- Advanced search
|Approved drug?||Yes (source: FDA (2013), EMA (2014))|
|International Nonproprietary Names|
|Search PubMed clinical trials||obinutuzumab|
|Search PubMed titles||obinutuzumab|
|Search PubMed titles/abstracts||obinutuzumab|
|Obinutuzumab is a third-generation, humanized and glyco-engineered anti-CD20 IgG1 mAb. Prior to 2009 obinutuzumab was known as afutuzumab.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.